GPRC5D-Directed Antibodies in Multiple Myeloma: New Agents and Frontline Strategies From IMS 2026

Clinical Lymphoma, Myeloma & Leukemia · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles